Skip to main
AIM

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech is a biotech company with a promising outlook due to a strong balance sheet, recent funding, and multiple ongoing clinical trials for its flagship products Ampligen and Alferon N Injection. Despite a lowered price target, analysts maintain a BUY rating for AIM based on its potential for growth and success in treating currently unmet medical needs. Positive clinical trial data for Ampligen in pancreatic and metastatic breast and colorectal cancers indicate the potential for high rewards in a billion dollar market, although there are still risks to achieving these goals in the long term.

Bears say

AIM ImmunoTech is a biopharmaceutical company with a negative outlook due to its limited cash reserves, high debt levels, and consistent net losses. While maintaining a BUY rating, analysts have lowered their 12-month price target to $22 based on NPV analysis, reflecting the company's high risks despite its growth prospects and potential for upside. The recent Q4 2025 results also fell below expectations with a higher-than-expected net loss, signaling uncertainties in the company's early/clinical stage drug development. Overall, there are significant fundamental concerns surrounding AIM ImmunoTech's financials and performance which may limit its potential for long-term success.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.